REG - Sareum Holdings PLC - Institutional Equity Fundraise

Sareum HoldingsAnnouncement

13/03/2025 07:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250313:nRSM5329Aa&default-theme=true

RNS Number : 5329A  Sareum Holdings PLC  13 March 2025

 

THIS ANNOUNCEMENT (INCLUDING THE APPENDICES) (THE "ANNOUNCEMENT") AND THE
INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE
OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE
UNITED STATES OF AMERICA, ITS STATES, TERRITORIES AND POSSESSIONS ("UNITED
STATES"), AUSTRALIA, CANADA, JAPAN, SINGAPORE, THE REPUBLIC OF SOUTH AFRICA OR
ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION
WOULD BE PROHIBITED BY ANY APPLICABLE LAW.

THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER TO SELL OR ISSUE OR THE
SOLICITATION TO BUY, SUBSCRIBE FOR OR OTHERWISE ACQUIRE ANY SECURITIES.

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATION (EU) 596/2014 AS IT FORMS PART OF UK DOMESTIC LAW
BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR"), AND IS
DISCLOSED IN ACCORDANCE WITH THE COMPANY'S OBLIGATIONS UNDER ARTICLE 17 OF
MAR.

 

Sareum Holdings PLC

("Sareum" or the "Company")

Institutional Equity Fundraise

Cambridge, UK, 13(th) March 2025 - Sareum Holdings plc (AIM: SAR), a
clinical-stage biotechnology company developing next-generation kinase
inhibitors for autoimmune disease and cancer, announces that it has
conditionally raised gross proceeds of £1.07 million by means of a
subscription (the "Subscription") for 8,560,000 new ordinary shares of 1.25
pence each in the capital of the Company ("Ordinary Shares") with an
institution  (the "Subscription Shares") at a price of 12.5 pence per new
Ordinary Share (the "Subscription Price").  The net proceeds from the
Subscription will be used to support the development of the expanded portfolio
and for general working capital purposes.

The Subscription Price represents a discount of approximately 24% to the
closing mid- market price for Sareum shares on 12(th) March 2025.

Admission and Total Voting Rights

The Company has applied for 8,560,000 Subscription Shares to be to be admitted
to trading on AIM ("Admission") by 8.00 a.m. on or around 18(th) March 2025.

The Subscription Shares will, when issued, be credited as fully paid and will
rank pari passu in all respects with the existing Ordinary Shares of the
Company including the right to receive all dividends or other distributions
made, paid or declared in respect of such shares after Admission. Admission is
conditional on all funds having been received from subscribers pursuant to the
Subscription.

Following Admission, the total number of Ordinary Shares in issue will be
133,487,651 and the total number of voting rights will thereafter be
133,487,651 and this figure may be used by shareholders as the denominator for
the calculations by which they will determine if they are required to notify
their interest in, or a change to their interest in, the share capital of the
Company under the FCA's Disclosure Guidance and Transparency Rules.

Dr Stephen Parker, Executive Chairman of Sareum, commented: "We are delighted
by the continued support and look forward to developing the portfolio, now
including SRA737, as we look to build value for our shareholders."

- Ends -

 

For further information, please contact:

 Sareum Holdings plc

 Stephen Parker, Executive Chairman         01223 497700

                                            ir@sareum.co.uk
 Strand Hanson Limited (Nominated Adviser)

 James Dance / James Bellman                020 7409 3494

 Oberon Capital (Joint Broker)              0203 179 5300

 Mike Seabrook / Nick Lovering

 Hybridan LLP (Joint Broker)                020 3764 2341

 Claire Noyce

 ICR Healthcare (Financial PR)

 Jessica Hodgson / Davide Salvi             0203 709 5700

 

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation
kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which
modify the activity of the JAK kinase family and have best-in-class potential.
Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801
is a potential treatment for a range of autoimmune diseases, including
psoriasis, and has completed Phase 1 clinical development.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential
application for cancer immunotherapy.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market
of the London Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at www.sareum.com
(about:blank) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEEAXDDFFDSEEA